Clinical trial
Faslodex Advanced Breast Cancer Local Chinese Study
NCT00327769 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00327769 |
|---|---|
| Title | Faslodex Advanced Breast Cancer Local Chinese Study |
| Official title | A Double Blind, Double Dummy, Randomised, Multicentre Study to Compare the Efficacy and Safety of Fulvestrant 250mg With Arimidex 1mg as a Secondary-line Therapy in the Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Advanced Breast Cancer |
| Intervention type | Drug |
| Interventions | Fulvestrant, Anastrozole |
| Enrollment | 234 |
| Start date | Nov 1, 2005 |
| Completion | Sep 1, 2007 |
| First posted | May 19, 2006 |
| Last update posted | Jan 25, 2011 |
| Countries | China |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: